NOAC in patients with VTE and polycythemia vera or essential thrombocythemia: a cohort study

Patients received apixaban (39.6%), rivaroxaban (33.3%), or dabigatran (27.1%). During a median follow-up of 30 (IQR, 20.5 – 41.5) months, recurrent ...

Source link